Knocking down ZDHHC12 disrupts CLDN3 membrane targeting/stability and impairs ovarian cancer tumorigenicity, highlighting ZDHHC12 as a therapeutic target (130). The gene discussed is CLDN3; the disease is ovarian carcinoma.